| pubmed-article:17928997 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0073393 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0080093 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C1446409 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0205322 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C1555029 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C1306673 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0443199 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C1152805 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0205263 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C1709060 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C1521801 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0205275 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0813872 | lld:lifeskim |
| pubmed-article:17928997 | lifeskim:mentions | umls-concept:C0920644 | lld:lifeskim |
| pubmed-article:17928997 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:17928997 | pubmed:dateCreated | 2008-1-22 | lld:pubmed |
| pubmed-article:17928997 | pubmed:abstractText | Latent inhibition (LI) is the poorer conditioning to a stimulus resulting from its nonreinforced preexposure. LI indexes the ability to ignore irrelevant stimuli and is used extensively to model attentional impairments in schizophrenia (SZ). We showed that rats and mice treated with the N-methyl-D-aspartic acid (NMDA) receptor antagonist MK801 expressed LI under conditions preventing LI expression in controls. This abnormally persistent LI was reversed by the atypical antipsychotic drug (APD) clozapine and by compounds enhancing NMDA transmission via the glycineB site, but not by the typical APD haloperidol, lending the MK801 LI model predictive validity for negative/cognitive symptoms. | lld:pubmed |
| pubmed-article:17928997 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17928997 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17928997 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17928997 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:17928997 | pubmed:issn | 0033-3158 | lld:pubmed |
| pubmed-article:17928997 | pubmed:author | pubmed-author:DiamantLL | lld:pubmed |
| pubmed-article:17928997 | pubmed:author | pubmed-author:RubioBB | lld:pubmed |
| pubmed-article:17928997 | pubmed:author | pubmed-author:WeinerII | lld:pubmed |
| pubmed-article:17928997 | pubmed:author | pubmed-author:Gaisler-Salom... | lld:pubmed |
| pubmed-article:17928997 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17928997 | pubmed:volume | 196 | lld:pubmed |
| pubmed-article:17928997 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17928997 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17928997 | pubmed:pagination | 255-67 | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:meshHeading | pubmed-meshheading:17928997... | lld:pubmed |
| pubmed-article:17928997 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:17928997 | pubmed:articleTitle | Abnormally persistent latent inhibition induced by MK801 is reversed by risperidone and by positive modulators of NMDA receptor function: differential efficacy depending on the stage of the task at which they are administered. | lld:pubmed |
| pubmed-article:17928997 | pubmed:affiliation | Department of Psychology, Tel Aviv University, Tel Aviv, Israel. | lld:pubmed |
| pubmed-article:17928997 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17928997 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:17928997 | lld:pubmed |
